The Fosun-backed gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.
Gyroscope Therapeutics, the UK-headquartered gene therapy developer backed by conglomerate Fosun, postponed its initial public offering on Friday.
Founded in 2016, Gyroscope has a gene therapy known as GT005 which is currently in phase 2 clinical trials for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a condition which can cause blindness.
The company had filed last month to raise up to $100m in an IPO on the Nasdaq Global Select Market and had set a range…
